# Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes

Study · id `cardio:ct-nct07383155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07383155](<https://clinicaltrials.gov/study/NCT07383155>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07383155

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 5270 participants.

## Technical summary

Registry record NCT07383155. Randomized; no masking; primary purpose treatment. Start 2026-02-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 5270 participants (planned count; ClinicalTrials.gov record NCT07383155, source copy `cardio:ctgov-nct07383155-2026-02-03`, retrieved 2026-10-31)
- Planned start: 2026-02-01 (anticipated) (ClinicalTrials.gov record NCT07383155, source copy `cardio:ctgov-nct07383155-2026-02-03`, retrieved 2026-10-31)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07383155, source copy `cardio:ctgov-nct07383155-2026-02-03`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07383155, source copy `cardio:ctgov-nct07383155-2026-02-03`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07383155-2026-02-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes
- Acronym: BRIGHT-HBR
- Condition: Percutaneous Coronary Intervention
- Condition: High Bleeding Risk
- Condition: Acute Coronary Syndromes
- Condition: Anticoagulant Therapy
- Intervention (Drug): Anticoagulant Therapy
- Lead sponsor: Shenyang Northern Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: Shenyang Northern Hospital (`cardio:org-shenyang-northern-hospital`)

## Provenance

Content hash: a43049f36a2021ed2ccdc25f6a1430124ad68761ca3190bb8c6b32a1ab753e17
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
